FDA lifts partial hold on Arcellx’s blood cancer cell therapy as biotech aims for 2026 launch

Arcellx’s Gilead-partnered multiple myeloma cell therapy is in the clear, as the FDA has removed the partial clinical hold it placed on the CAR-T candidate in June following a patient death.

The California drugmaker said Monday that the patient who died was “managed in a…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks